FEMY · Femasys Inc
$2.12
+0.02 (+0.95%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 8, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$20.77M
Shares
8.38M
Volume · Oct 1
51.88K
Avg daily vol (3M)
714.62K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.10
Open$2.17
Day$2.10–2.24
52W close$2.09–20.80
Avg vol 30d160K
Short int613K · 7.3% float · 8.5d
Short vol37%
Last earningsMar 21, 2024
DataJun 2021–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.30M
Trailing 12 months
Net income (TTM)
−$11.77M
Trailing 12 months
Revenue growth YoY
-18.9%
Year over year
Operating margin
-763.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-87.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.44M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+132.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.3%
Latest settlement · 8.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−72%
below
Price vs 50-day avg
−23%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−74%
trailing
YTD return
−82%
this year
Relative strength
−86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$134.0K over 90 days · 0% sells
Short interest
Rising
7.31% of float · ▲ +3.3% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
18 holders — near 3-yr low, contrarian setup
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+41%
Y/Y
Gross margin
33%
contracting
EPS growth
+45%
Y/Y
Free cash flow
$-19.2M
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−72%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$134.0K over 90 days · 0% sells
Short interest
Rising
7.31% of float · ▲ +3.3% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
18 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $21
vs 200-day avg -72%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FEMY
this stock
Femasys Inc
|
$20.77M | — | +40.8% | — | 7.3% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -29.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -16.8% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FEMY | -13.6% | -32.3% | -73.6% | -2.8% | -81.8% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -13.2% | -32.1% | -86.0% | -3.0% | -93.8% |